Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/29/2025 | $44.00 | Neutral → Overweight | Piper Sandler |
Piper Sandler upgraded Claritev from Neutral to Overweight and set a new price target of $44.00
Strategic leadership and operational collaboration underscore Claritev's commitment to growth in the Middle East and international business development outside the US Claritev Corporation ("Claritev") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced it is deepening its investment in the Middle East North Africa ("MENA") region and the market outside the United States with the appointment of new regional leadership and a strategic operational collaboration. These moves reflect Claritev's continued focus on expanding its footprint and delivering localized, high-impact healthcare technology soluti
HOLLYWOOD, Fla., May 06, 2025 (GLOBE NEWSWIRE) -- Great Speech, a national leader in virtual speech therapy, is proud to announce a new agreement with Claritev, formerly known as MultiPlan (NYSE:CTEV), a technology and data insights company focused on making healthcare more affordable, transparent and fair for all. This network participation agreement marks a major step forward in expanding access to high-quality, convenient, and personalized speech therapy services for individuals and families nationwide. Great Speech's innovative teletherapy services will now be available to health plan members accessing Claritev's MultiPlan and PHCS Networks. The initiative aims to eliminate traditio
Board gains deep technology and innovation expertise to support Claritev's tech-driven growth strategy Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, yesterday announced the appointment of Jason Kap to its Board of Directors, effective immediately following his election at the Company's Annual Meeting of Shareholders on April 30, 2025. Kap brings more than two decades of leadership experience driving technology, pricing and product transformation strategies across the software and services industries, strengthening Claritev's focus on building a next-generati
– Q1 2025 Revenues of $231.3 million, Net Loss of $71.3 million, and Adjusted EBITDA of $142.1 million (Adjusted EBITDA Margin of 61.4%) – Reaffirms full-year guidance Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the first quarter ended March 31, 2025. "There is tremendous excitement at Claritev as we kick off 2025 - our ‘Year of The Turn.' We've already announced major milestones, and our teams are amplifying this positive momentum as we continue on our planned course for the year," said Travis Dalton, Chairman, CEO a
Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, announced today that it will release its first quarter 2025 financial results on Thursday, May 8, 2025, and hold its conference call that morning at 8:00 am Eastern Time. To join the conference call, please pre-register using the link below. Participants who pre-register will receive a calendar invitation with call access details including a unique PIN. Pre-registration may be completed at any time up to and following the call start time. To pre-register, go to: https://www.netroadshow.com/events/login?show=fda0
Strategic leadership and operational collaboration underscore Claritev's commitment to growth in the Middle East and international business development outside the US Claritev Corporation ("Claritev") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced it is deepening its investment in the Middle East North Africa ("MENA") region and the market outside the United States with the appointment of new regional leadership and a strategic operational collaboration. These moves reflect Claritev's continued focus on expanding its footprint and delivering localized, high-impact healthcare technology soluti
This agreement follows the previous announcement of a memorandum of understanding signed last month. Claritev Corporation ("Claritev") (NYSE:CTEV) and Claims Care Revenue Cycle Management LLC ("Claims Care" or "CCRCM"), a division of Burjeel Holdings (ADX: BURJEEL), are pleased to announce the formalization of their strategic relationship, following the signing of a memorandum of understanding ("MoU") announced last month. This collaboration aims to revolutionize revenue cycle management ("RCM") in the Middle East and North Africa ("MENA") region by bringing the power of Claritev's advanced claims analytics and AI-driven solutions together with Claims Care's extensive regional expertise.
– Q1 2025 Revenues of $231.3 million, Net Loss of $71.3 million, and Adjusted EBITDA of $142.1 million (Adjusted EBITDA Margin of 61.4%) – Reaffirms full-year guidance Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the first quarter ended March 31, 2025. "There is tremendous excitement at Claritev as we kick off 2025 - our ‘Year of The Turn.' We've already announced major milestones, and our teams are amplifying this positive momentum as we continue on our planned course for the year," said Travis Dalton, Chairman, CEO a
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
S-8 - Claritev Corp (0001793229) (Filer)
10-Q - Claritev Corp (0001793229) (Filer)
8-K - Claritev Corp (0001793229) (Filer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)